| Literature DB >> 29898765 |
David B Bartlett1,2,3, Leslie H Willis4, Cris A Slentz4, Andrew Hoselton4, Leslie Kelly4, Janet L Huebner4, Virginia B Kraus4, Jennifer Moss4, Michael J Muehlbauer4, Guillaume Spielmann5, William E Kraus4, Janet M Lord6,7, Kim M Huffman4.
Abstract
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease in which adults have significant joint issues leading to poor health. Poor health is compounded by many factors, including exercise avoidance and increased risk of opportunistic infection. Exercise training can improve the health of patients with RA and potentially improve immune function; however, information on the effects of high-intensity interval training (HIIT) in RA is limited. We sought to determine whether 10 weeks of a walking-based HIIT program would be associated with health improvements as measured by disease activity and aerobic fitness. Further, we assessed whether HIIT was associated with improved immune function, specifically antimicrobial/bacterial functions of neutrophils and monocytes.Entities:
Keywords: Disease activity; High-intensity interval exercise; Inflammation; Innate immunity; Rheumatoid arthritis
Mesh:
Substances:
Year: 2018 PMID: 29898765 PMCID: PMC6001166 DOI: 10.1186/s13075-018-1624-x
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Before and after high-intensity interval training values, CIs, and effect sizes for clinical characteristics, health and disease activity, and medication use
| Pre-HIIT | Post-HIIT | 95% CI (lower, upper) | Effect size ( | ||
|---|---|---|---|---|---|
| Age, yr | 64 ± 7 | ||||
| Sex, M/F | 1/11 | ||||
| Clinical characteristics | |||||
| BMI, kg/m2 | 27.4 ± 9.3 | 27.7 ± 9.8 | (− 0.6, 0.1) | 0.191 | 0.40 |
| Body fat, % | 36.6 ± 11.6 | 37.3 ± 11.2 | (− 2.1, 0.7) | 0.294 | 0.32 |
| Blood pressure, mmHg | |||||
| Systolic | 136 ± 14 | 127 ± 14 | (− 0.8, 17.3) | 0.070 | 0.58 |
| Diastolic | 73 ± 12 | 69 ± 8 | (− 2.7, 8.1) | 0.064 | 0.60 |
| Mean arterial pressure | 94 ± 11 | 89 ± 9 | (0.2, 10.3) | 0.044 | 0.66 |
| Resting heart rate, beats/min | 69 ± 8 | 64 ± 8 | (1.5, 8.3) | 0.009 | 0.91 |
| HbA1c, % | 5.6 ± 0.5 | 5.6 ± 0.4 | (− 0.1, 0.2) | 0.898 | 0.04 |
| Health and disease activity | |||||
| HAQ-DI | 0.42 ± 0.35 | 0.39 ± 0.47 | (− 0.1, 0.2) | 0.614 | 0.16 |
| Pain | 28.7 ± 29.8 | 20.3 ± 21.5 | (− 7.3, 24.1) | 0.262 | 0.34 |
| Anxiety | 4.1 ± 2.6 | 3.5 ± 2.8 | (− 0.9, 2.0) | 0.393 | 0.25 |
| Depression | 3.8 ± 2.5 | 2.4 ± 1.9 | (0.1, 2.5) | 0.031 | 0.71 |
| Swollen joints, | 4.3 ± 3.8 | 1.9 ± 1.7 | (0.6, 4.2) | 0.013 | 0.85 |
| Tender joints, | 4.3 ± 7 | 1.9 ± 2.8 | (− 0.8, 5.4) | 0.062 | 0.48 |
| Global health, mm | 31.5 ± 15.7 | 22.6 ± 19.2 | (0.6, 17.2) | 0.037 | 0.85 |
| DAS28ESR | 3.1 ± 1.6 | 2.3 ± 1.2 | (0.4, 1.2) | 0.001 | 1.23 |
| DAS28CRP | 3.1 ± 1.2 | 2.4 ± 1 | (0.3, 1.0) | 0.001 | 1.26 |
| ESR, mm/h | 10.5 ± 11.9 | 7 ± 8.8 | (0.04, 6.5) | 0.023 | 0.65 |
| CRP, mg/L | 2.7 ± 3.5 | 2.2 ± 3.1 | (− 0.6, 1.6) | 0.322 | 0.30 |
| Medication use, | |||||
| Infliximab | 2 (17%) | ||||
| Adalimumab | 2 (17%) | ||||
| Methotrexate | 6 (50%) | ||||
| Leflunomide | 1 (8%) | ||||
| Sulfasalazine | 2 (17%) | ||||
| Tofacitinib | 1 (8%) | ||||
| Hydroxychloroquine | 4 (33%) | ||||
| NSAID | 8 (67%) | ||||
| Prednisone | 2 (17%) | ||||
Abbreviations: HIIT High-intensity interval training, HbA1c Hemoglobin A1c, BMI Body mass index, HAQ-DI Health Assessment Questionnaire Disability Index, DAS28 Disease Activity Score in 28 joints, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, NSAID Nonsteroidal anti-inflammatory drug
Data are mean ± SD
Before and after high-intensity interval training values, CIs, and effect sizes for cardiorespiratory fitness and physical function
| Pre-HIIT | Post-HIIT | 95% CI (lower, upper) | Effect size ( | ||
|---|---|---|---|---|---|
| Cardiorespiratory fitness | |||||
| VO2peak, L/min | 1.75 ± 0.4 | 1.89 ± 0.4 | (− 3.0, − 1.8) | < 0.001 | 2.86 |
| VO2peak, ml/kg/min | 25.0 ± 6.6 | 27.1 ± 7.0 | (− 0.2, − 0.13) | < 0.001 | 3.19 |
| Physical function | |||||
| Physical activity questionnaires | |||||
| IPEQ | 30.4 ± 24.6 | 28.8 ± 16.7 | (− 11.2, 14.4) | 0.788 | 0.08 |
| SBAS | 2.5 ± 0.5 | 2.9 ± 1.0 | (− 0.9, 0.1) | 0.096 | 0.52 |
| Grip strength, kg | 18.3 ± 7.2 | 19.0 ± 8.1 | (− 1.7, 0.3) | 0.166 | 0.43 |
| Berg Balance Score | 54.4 ± 4.0 | 54.7 ± 3.2 | (− 1.2, 0.7) | 0.555 | 0.18 |
| TUG, s | 8.8 ± 1.8 | 8.4 ± 1.9 | (− 0.1, 0.1) | 0.084 | 0.54 |
| 400-m walk test, s | 251 ± 62 | 233 ± 51 | (9.0, 27.4) | 0.001 | 1.30 |
| 30-s chair stands, | 14 ± 4 | 17 ± 5 | (− 4.0, − 0.2) | 0.035 | 0.70 |
Abbreviations: HIIT High-intensity interval training, IPEQ Incidental and Planned Exercise Questionnaire, SBAS Stanford Brief Activity Survey, TUG Timed Up and Go, VO2peak Aerobic capacity
Data are mean ± SD
Before and after high-intensity interval training values, CIs, and effect sizes for systemic inflammation, white blood cell counts, glucose, insulin and insulin resistance, and nonesterified fatty acid concentrations
| Pre-HIIT | Post-HIIT | 95% CI (lower, upper) | Effect size ( | ||
|---|---|---|---|---|---|
| Systemic inflammation | |||||
| IL-1β, pg/ml | 0.12 ± 0.13 | 0.12 ± 0.11 | (− 0.04, 0.06) | 0.788 | 0.07 |
| IL-6, pg/ml | 1.06 ± 0.89 | 1.43 ± 2.02 | (− 1.6, 0.8) | 0.519 | 0.19 |
| CXCL-8, pg/ml | 9.69 ± 6.97 | 10.3 ± 10.0 | (− 3.3, 2.2) | 0.655 | 0.13 |
| IL-10, pg/ml | 0.5 ± 0.4 | 0.5 ± 0.3 | (− 0.1, 0.1) | 0.912 | 0.03 |
| TNF-α, pg/ml | 2.21 ± 0.96 | 2.31 ± 0.96 | (− 0.5, 0.3) | 0.570 | 0.17 |
| White blood cells, ×106/L | |||||
| Total count | 5.6 ± 1.1 | 5.8 ± 1.2 | (− 0.6, 0.2) | 0.322 | 0.32 |
| Neutrophils | 2.8 ± 0.8 | 2.9 ± 0.9 | (− 0.5, 0.1) | 0.217 | 0.40 |
| Lymphocytes | 2.0 ± 0.6 | 2.1 ± 0.6 | (− 0.4, 0.2) | 0.623 | 0.15 |
| Monocytes | 0.6 ± 0.2 | 0.6 ± 0.2 | (− 0.1, 0.1) | 0.676 | 0.12 |
| Eosinophils | 0.3 ± 0.3 | 0.2 ± 0.1 | (− 0.02, 0.2) | 0.108 | 0.53 |
| Neutrophils: lymphocytes | 1.5 ± 0.6 | 1.5 ± 0.5 | (− 0.4, 0.3) | 0.810 | 0.07 |
| Glucose, insulin, and NEFA | |||||
| Fasting glucose (mg/dl) | 90.9 ± 7.7 | 93.1 ± 8.3 | (− 4.8, 0.5) | 0.098 | 0.55 |
| Fasting insulin, μIU/ml | 13 ± 4.9 | 12 ± 4.8 | (− 0.8, 2.7) | 0.264 | 0.34 |
| HOMA-IR | 1.67 ± 0.64 | 1.56 ± 0.62 | (− 0.1, 0.3) | 0.258 | 0.34 |
| NEFA, mmol/L | 0.55 ± 0.37 | 0.60 ± 0.36 | (− 0.2, 0.1) | 0.412 | 0.24 |
Abbreviations: HIIT High-intensity interval training, IL Interleukin, CXCL Chemokine C-X-C motif ligand, TNF-α Tumor necrosis factor-α, HOMA-IR Homeostatic model of assessment of insulin resistance, NEFA Nonesterified fatty acids
Data are mean ± SD
Fig. 1Neutrophil migratory changes following high-intensity interval training (HIIT). Neutrophils were migrated toward chemokine (C-X-C motif) ligand CXCL-8 and assessed pre- and post-HIIT for 10 weeks for overall chemotactic accuracy, known as the chemotactic index (a); directional speed, known as chemotaxis (b); and overall speed, known as chemokinesis (c). All data are mean ± SEM (n = 12)
Fig. 2Neutrophil changes in response to 10 weeks of high-intensity interval training (HIIT). Representative flow cytometric histograms showing (a) improved neutrophil phagocytosis of Escherichia coli, (b) phagocytic capacity, (c) representative diagram of the kinetic phorbol 12-myristate 13-acetate-stimulated ROS production, and (d) ROS generation (AUC) and neutrophil surface receptor expression pre- and post-HIIT training for (e) CXC chemokine receptor 2 (CXCR2), (f) cluster of differentiation 11b (CD11b)/CD18, (g) Toll-like receptor 4 (TLR4), and (h) CD16. All data are mean ± SEM (n = 12). MFI Median fluorescence intensity
Fig. 3Monocyte changes in response to 10 weeks of high-intensity interval training (HIIT). a Representative forward vs. side scatter of cluster of differentiation 16 (CD16) expression on CD14+ monocytes. Frequency of (b) total CD16-expressing monocytes, (c) intermediate monocytes, and (d) nonclassical monocytes pre- and post-HIIT training. Surface expression of (e) Toll-like receptor 2 (TLR2), (f) TLR4, and (g) human leukocyte antigen (HLA)-DR on intermediate monocytes pre- and post-HIIT training. h Phagocytosis of fluorescein isothiocyanate-labeled Escherichia coli pre- and post-HIIT training. All data are mean ± SEM (n = 12). MFI Median fluorescence intensity